Investors

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient´s dendritic cells to activate an immune response specific to the patient´s disease. Argos´ most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV.


Stock Quote

NASDAQ: ARGS
1.30
- 0.05 (-3.70%)

Day High:
1.35

Day Low:
1.25

Volume:
827,566

11:47 AM ET on Feb 24, 2017
Delayed at least 20 minutes.